Promising drug combo shows progress against advanced breast cancer
NCT ID NCT03671330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug ribociclib to standard hormone therapy helps slow the growth of advanced breast cancer in Chinese women. About 327 women with a specific type of breast cancer (HR+, HER2-) took part. The main goal was to see how long the cancer stayed under control. This is not a cure, but aims to manage the disease and delay progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Hefei, Anhui, 230001, China
-
Novartis Investigative Site
Beijing, Beijing Municipality, 100044, China
-
Novartis Investigative Site
Chongqing, Chongqing Municipality, 404100, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050011, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150081, China
-
Novartis Investigative Site
Changsha, Hunan, 410013, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
Suzhou, Jiangsu, 215004, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330009, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Shengyang, Liaoning, 110016, China
-
Novartis Investigative Site
Shengyang, Liaoning, 110042, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310016, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Fuzhou, 350001, China
-
Novartis Investigative Site
Qingdao, 266000, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300480, China